Literature DB >> 1812437

The epidemiology of meningococcal disease in Norway 1975-91.

A Lystad1, S Aasen.   

Abstract

The epidemiology of meningococcal disease (MCd) in Norway is described on the basis of official notification figures for 1975-91. Morbidity is presented by serogroup of the isolated Neisseria meningitidis strain, time of onset of the disease in addition to the place of living, age and sex of the patient. A long-term group B epidemic with high incidence and case fatality rates in the age groups below 5 years and between 13 and 19-20 years is the main characteristics of the situation.

Entities:  

Mesh：

Year:  1991        PMID： 1812437

Source DB:  PubMed          Journal:  NIPH Ann        ISSN： 0332-5652


  10 in total

1.  Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Authors:  Berit Feiring; Jan Fuglesang; Philipp Oster; Lisbeth M Naess; Oddveig S Helland; Sandrine Tilman; Einar Rosenqvist; Marianne A R Bergsaker; Hanne Nøkleby; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2006-07

2.  Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine.

Authors:  A Aase; G Bjune; E A Høiby; E Rosenqvist; A K Pedersen; T E Michaelsen
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

3.  Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.

Authors:  F Oftung; L M Naess; L M Wetzler; G E Korsvold; A Aase; E A Høiby; R Dalseg; J Holst; T E Michaelsen; B Haneberg
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

Review 4.  An epidemiological review of changes in meningococcal biology during the last 100 years.

Authors:  Anne Abio; Keith R Neal; Charles R Beck
Journal:  Pathog Glob Health       Date:  2013-12-19       Impact factor: 2.894

5.  Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985-2002.

Authors:  I Smith; A T Bjørnevik; I M B Augland; A Berstad; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

6.  Meningococcal serogroup Y emergence in Europe: update 2011.

Authors:  Michael Bröker; Susanne Jacobsson; Markku Kuusi; David Pace; Maria J Simões; Anna Skoczynska; Muhamed-Kheir Taha; Maija Toropainen; Georgina Tzanakaki
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

7.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

8.  Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis.

Authors:  O H Gilja; A Halstensen; A Digranes; H Mylvaganam; A Aksnes; E A Høiby
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

Review 9.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

10.  Carriers of Neisseria meningitidis in household contacts of meningococcal disease cases in Catalonia (Spain).

Authors:  N Cardeñosa; A Domínguez; A Orcau; H Pañella; P Godoy; S Minguell; N Camps; J A Vázquez
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.